Padcev/Keytruda Extends Survival in Early Bladder Cancer

Padcev/Keytruda extends survival in early bladder cancer

Astellas and Pfizer plan to file Padcev for earlier-stage bladder cancer after showing a survival benefit in a combination regimen with Keytruda.

Pfizer drug extends survival for some bladder cancer patients

Padcev, an antibody-drug conjugate that the drug giant acquired through its purchase of Seagen, was combined with Keytruda in clinical trial.

Pfizer’s Padcev Plus Keytruda Extends Bladder Cancer Survival

The combination of Padcev, a bladder cancer drug from Pfizer Inc. and Astellas Pharma Inc., and Merck & Co.’s blockbuster immunotherapy Keytruda extended the lives of patients with a hard-to-treat form of the disease.

PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

NEW YORK & TOKYO--(BUSINESS WIRE)--Aug 12, 2025-

Enfortumab Vedotin/Pembrolizumab Improved Survival Vs Surgery in MIBC

Patients with cisplatin-ineligible bladder cancer who received enfortumab vedotin plus pembrolizumab and surgery had prolonged survival vs those who received surgery alone.